Clinical Relevance of Gain-Of-Function Mutations of p53 in High-Grade Serous Ovarian Carcinoma

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Kang, Hyo Jeong ^a   Chun, Sung Min ^a   Kim, Kyu Rae ^a   Sohn, Insuk ^b   Sung, Chang Ohk ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Samsung Advanced Institute of Technology (SAIT)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PLATINUM COMPLEX; PROTEIN P53;

ADULT; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; CPG ISLAND; DISTANT METASTASIS; DNA BASE COMPOSITION; EXOME; FEMALE; GAIN OF FUNCTION MUTATION; GENE ACTIVITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RNA SEQUENCE; SOMATIC MUTATION;

ADULT; AGED; BASE COMPOSITION; CARCINOMA; CPG ISLANDS; DRUG RESISTANCE, NEOPLASM; EXOME; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASM STAGING; OVARIAN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84881510929     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072609     Document Type: Article

References (32)

1. Muller PA, Vousden KH, (2013) p53 mutations in cancer. Nat Cell Biol 15: 2-8. doi:10.1038/ncb2641. PubMed: 23263379.
2. Olivier M, Hollstein M, Hainaut P, (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2: a001008. doi:10.1101/cshperspect.a001008. PubMed: 20182602.
3. Rivlin N, Brosh R, Oren M, Rotter V, (2011) Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer 2: 466-474. doi:10.1177/1947601911408889. PubMed: 21779514.
4. Oren M, Rotter V, (2010) Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2: a001107. doi:10.1101/cshperspect.a001107. PubMed: 20182618.
5. Heinlein C, Krepulat F, Löhler J, Speidel D, Deppert W, et al. (2008) Mutant p53(R270H) gain of function phenotype in a mouse model for oncogene-induced mammary carcinogenesis. Int J Cancer 122: 1701-1709. PubMed: 18092324.
6. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, et al. (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872. doi:10.1016/j.cell.2004.11.006. PubMed: 15607981.
7. Doyle B, Morton JP, Delaney DW, Ridgway RA, Wilkins JA, et al. (2010) p53 mutation and loss have different effects on tumourigenesis in a novel mouse model of pleomorphic rhabdomyosarcoma. J Pathol 222: 129-137. doi:10.1002/path.2748. PubMed: 20662002.
8. Liu G, McDonnell TJ, Montes de Oca Luna R, Kapoor M, Mims B, et al. (2000) High metastatic potential in mice inheriting a targeted p53 missense mutation. Proc Natl Acad Sci U S A 97: 4174-4179. doi:10.1073/pnas.97.8.4174. PubMed: 10760284.
9. Morton JP, Timpson P, Karim SA, Ridgway RA, Athineos D, et al. (2010) Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc Natl Acad Sci U S A 107: 246-251. doi:10.1073/pnas.0908428107. PubMed: 20018721.
10. Muller PA, Vousden KH, Norman JC, (2011) p53 and its mutants in tumor cell migration and invasion. J Cell Biol 192: 209-218. doi:10.1083/jcb.201009059. PubMed: 21263025.
11. Cho Y, Gorina S, Jeffrey PD, Pavletich NP, (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265: 346-355. doi:10.1126/science.8023157. PubMed: 8023157.
12. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, et al. (2010) Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 221: 49-56. doi:10.1002/path.2696. PubMed: 20229506.
13. Wojnarowicz PM, Oros KK, Quinn MC, Arcand SL, Gambaro K, et al. (2012) The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome. PLOS ONE 7: e45484. doi:10.1371/journal.pone.0045484. PubMed: 23029043.
14. The Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
15. Muench P, Probst S, Schuetz J, Leiprecht N, Busch M, et al. (2010) Cutaneous papillomavirus E6 proteins must interact with p300 and block p53-mediated apoptosis for cellular immortalization and tumorigenesis. Cancer Res 70: 6913-6924. doi:10.1158/0008-5472.CAN-10-1307. PubMed: 20663910.
16. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, et al. (2006) Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 5: 2512-2521. doi:10.1158/1535-7163.MCT-06-0334. PubMed: 17041095.
17. Sohn I, Jung WY, Sung CO, (2012) Somatic hypermutation and outcomes of platinum based chemotherapy in patients with high grade serous ovarian cancer. Gynecol Oncol 126: 103-108. doi:10.1016/j.ygyno.2012.03.050. PubMed: 22484402.
18. Sohn I, Sung CO, (2013) Predictive modeling using a somatic mutational profile in ovarian high grade serous carcinoma. PLOS ONE 8: e54089. doi:10.1371/journal.pone.0054089. PubMed: 23326577.
19. Carlsson J, Soussi T, Persson B, (2009) Investigation and prediction of the severity of p53 mutants using parameters from structural calculations. FEBS J 276: 4142-4155. doi:10.1111/j.1742-4658.2009.07124.x. PubMed: 19558493.
20. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28: 622-629. doi:10.1002/humu.20495. PubMed: 17311302.
21. Simon R, Lam A, Li MC, Ngan M, Menenzes S, et al. (2007) Analysis of gene expression data using BRB-ArrayTools. Cancer INFORM 3: 11-17. PubMed: 19455231.
22. Tusher VG, Tibshirani R, Chu G, (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121. doi:10.1073/pnas.091062498. PubMed: 11309499.
23. Blandino G, Levine AJ, Oren M, (1999) Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18: 477-485. doi:10.1038/sj.onc.1202314. PubMed: 9927204.
24. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, et al. (2009) A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137: 87-98. doi:10.1016/j.cell.2009.01.039. PubMed: 19345189.
25. Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, et al. (2011) Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ 18: 271-281. doi:10.1038/cdd.2010.94. PubMed: 20689556.
26. Wang SP, Wang WL, Chang YL, Wu CT, Chao YC, et al. (2009) p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol 11: 694-704. doi:10.1038/ncb1875. PubMed: 19448627.
27. Li Y, Guessous F, Kwon S, Kumar M, Ibidapo O, et al (2008) PTEN has tumor-promoting properties in the setting of gain-of-function p53 mutations. Cancer Res 15: 1723-1731.
28. Persad S, Troussard AA, McPhee TR, Mulholland DJ, Dedhar S, (2001) Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. J Cell Biol 153: 1161-1174. doi:10.1083/jcb.153.6.1161. PubMed: 11402061.
29. Bowtell DD, (2010) The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10: 803-808. doi:10.1038/nrc2946. PubMed: 20944665.
30. Sabatier R, Finetti P, Cervera N, Birnbaum D, Bertucci F, (2009) Gene expression profiling and prediction of clinical outcome in ovarian cancer. Crit Rev Oncol/Hematol 72: 98-109. doi:10.1016/j.critrevonc.2009.01.007. PubMed: 19249225.
31. Bookman MA, (2003) Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 21: 149s-167s. doi:10.1200/JCO.2003.02.553. PubMed: 17633784.
32. Miller DS, Blessing JA, Krasner CN, Mannel RS, Hanjani P, et al. (2009) Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol 27: 2686-2691. doi:10.1200/JCO.2008.19.2963. PubMed: 19332726.